Skip to content

Tag: COVID-19 vaccine

Published on Leave a comment on What About Me?

This week I realized covid shares a characteristic with my granddaughter. Sometimes, when she is the only child in a room full of adults taking about endless banalities, she interrupts us with a "What about me?" plea. Every week I gather potential topics for this blog from key medical journal email alerts, feeds from a few selected sources like CIDRAP, scanning the Washington Post, New York Times, and Wall Street Journal dailies, watching national news broadcasts when I can, and just generally keeping my eyes and ears open. I must see dozens of potential topics to include next week, and I bookmark a subset to reconsider at the end of the week.

This week I had a few more topics than usual, around 20, that I needed to winnow down. I quickly realized that all but 1 of them were related to covid. Try as I might to include topics on general infectious diseases, covid has succeeded in becoming the center of attention this week. I'll do my best to summarize a few of the pearls.

Covid Vaccine Updates

Pediatric healthcare providers can rejoice in some more good news: according to the AAP, Moderna has joined Pfizer in allowing free returns of unused covid vaccine doses, making it less financially risky for practices to order vaccine.

A few new studies confirm high vaccine effectiveness extending into the omicron era. First, a cohort study in 4 Nordic countries looked at mRNA covid vaccine effectiveness in adolescents completing 2 vaccine doses between approximately April 2021 and April 2023. A little over 500,000 subjects were included. Vaccine effectiveness against hospitalization was 72.6% (95% CI 62.5-82.7) with a suggestion that heterologous dosing (1 Pfizer dose and 1 Moderna dose) had slightly higher effectiveness at 86.0% (56.8-100). Similar numbers were seen when just the omicron time period was analyzed at follow-up periods of 6 and 12 months. It's important to note that hospitalizations were relatively rare, regardless of vaccine status, as expected in an adolescent population. (Norway isn't included below because too few hospitalizations occurred to allow for analysis.)

Another study looked at VE in US children (5-11 yo) and adolescents (12-20 yo), the latter group in both delta and omicron periods and the former group only during the omicron period (no vaccine was available for the younger group during the delta wave). It looked at a "real world" population, i.e. not part of a formal research study but rather examining vaccine usage as implemented after authorization/approval, using data available from 7 pediatric healthcare organizations. Again VE was high, For the Pfizer vaccine during the delta time period, VE against infection was 98.4% with narrow CI (those were the good-old days at least in this one feature, no covid vaccine has great VE against infection nowadays). During the early omicron period (up through November 2022), VE against infection was 74% in the younger children and 82% in the adolescents; durability of the protection was fairly stable over a 10-month follow-up period, although the CIs became very wide because so few events occurred.

Finally I'll mention a study in the "elderly" because it contains very recent data. In Denmark, VE reported as hazard ratios of the XBB variant-based vaccine (the one in use starting last fall) was highly effective against hospitalization in this older age group. Note the very short follow-up period, this information clearly is very preliminary and could change significantly as time passes.

Covid Epidemiology

The more interesting information about covid epidemiology this week comes from abroad. First, I loved this study from the UK because it used smartphone tracing technology, preserving confidentiality, to identify important determinants of covid transmission. A key finding was that the probability of person-to-person transmission increased with time, first linearly at 1.1% per hour of exposure but extending for several days. Household exposures were most likely to result in transmission. Distance played a role of course, but longer exposures at greater distances had about equal risk of transmission as shorter exposures at shorter distances. I could spend an entire blog post and more on this article. This information can provide excellent guidance for quarantining and distancing in the event of a large covid wave in the future. Remember that the original guidance earlier in the pandemic for distancing of 6 feet was mostly a best guess to prevent transmission, no great data to guide that advice.

A report from the UK government summarizes a wealth of data as the following (see page 3 of the pdf in the link):

"... COVID-19 Omicron variant cases were most infectious around symptom onset and up to 5 days after, but could potentially be infectious for longer, especially for cases that are hospitalised, immunocompromised, or otherwise high risk. Three studies looked at transmission before symptom onset. These suggested that between a third and a half of transmission events occurred before symptom onset in the index case. However, while some studies included substantial numbers of cases, most studies included relatively few cases, and the majority of studies included cases with Omicron variant BA.1 and BA.2, with only a small number of studies reporting evidence from 2023."

This information can help inform your discussions with all those parents who wonder about transmission to high risk family members and whether to risk exposure for a special event. If you want more data than you (or I) can handle about what's going on in the UK with covid, see this link. The Excel files are massive but very interesting for those of you who want to take a deep dive.

The final mention of epidemiology is a source for concern and caution. The Pan American Health Organization, PAHO, that is the branch of the WHO overseeing public health in the Americas, reported on respiratory illness activity in the southern hemisphere which is now in summer season. The key take-home point here is that, although North American is driving a lot of the SARS-CoV-2 positivity now, there is significant covid illness in Central and South America. This implies that covid is not quite a winter respiratory virus, at least not yet.

Covid Bottom Lines

As we enter our 4th year of covid, I realized I've learned a few key lessons to be applied for the future:

  • It's difficult to compare illness rates and other outcomes in the US over the years, primarily because we aren't collecting information in the same way as we did early in the pandemic. Wastewater data are mostly obtained as they were before, but this is at best a qualitative data source.
  • Covid vaccines are the most closely studied and monitored in history with now over 5 billion people worldwide receiving at least one dose. Every credible study/report has confirmed that, regardless of age or underlying risk factors, vaccinated individuals will have better outcomes than being unaccinated and infected, even after being infected multiple times. This takes into account all adverse events following vaccination itself. For virtually every individual, vaccination is the better choice. From a public health perspective, vaccination of some low risk groups may not be cost effective. This is why the UK, for example, does not provide vaccine for some healthy children; UK health authorities have decided the money is better spent on other aspects of health care.
  • Although there are similarities, SARS-CoV-2 is not just like influenza virus. The mutation rate is much higher, meaning that we still face a faster moving target for new vaccine and therapeutic drug development. Also, as mentioned above, seasonality isn't yet clear. So far SARS-CoV-2 isn't just a winter respiratory virus.
  • Even though the omicron era seems to have brought less disease severity, SARS-CoV-2 is still a major killer, now at a rate of about 1500 deaths per week.

Please encourage everyone to be up-to-date on covid and all other vaccines.

WRIS

Winter Respiratory Infection Season clearly is still with us. I await more data to see if the winter school break resulted in fewer, greater, or had no effect on WRIS infection numbers. However, I did notice a report from China that provided evidence that school breaks lessened influenza transmission during the years 2015-2018.

RSV-NET: CDC is still projecting a downturn nationally, but too early to be certain of this.

FluView still shows significant influenza-like illness activity, at least as of a week ago. It's definitely not too late to be vaccinated.

And ... More What About Me

It's my blog, what could be a more pitiful plea for attention? So, speaking of me, note that the CDC published the 2024 adult immunization guide that not only includes old codgers such as yours truly but also extends down to 19 years of age.

One last bit, an update to my bird feeder adventures I mentioned last week. I had a great few days of multiple bird species sightings, followed by a squirrel invasion - those dastardly rodents cleaned out the birdseed supply in a couple days. I've now been researching squirrel deterrents, being careful to not actually hurt them although I admit to having occasional sciuricidal thoughts. It looks like I'll be moving the feeder and engaging in some high-wire techniques to squirrel-proof the new location, hoping I don't end up with a spectacular ladder fall and resultant visit to my local ER.

Published on Leave a comment on Winter Distractions

My soon-to-be daughter-in-law recently gave me a bird feeder - not just any bird feeder, but a smart one that has a camera connected to my wifi that takes photos and videos of any birds that show up. I had my first visitors this morning, a few days after I stocked it with birdseed.

In the meantime, winter is here.

WRIS

A lot going on with our Winter Respiratory Infection Season, including some new items.

CDC issued new (or actually old) guidance for use of the long-acting monoclonal antibody nirsevimab for preventing RSV infection in young infants. The change was prompted by the announcement of greater availability of nirsevimab because the manufacturer released an additional 230,000 doses this month. Previously the guidance had indicated that the product should be prioritized for just a subset of infants at higher risk, but now recommendations are to go back to the original plan to administer to all infants less than 8 months of age as well as to infants 8-19 months of age with high risk conditions:

  • Children who have chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season
  • Children with severe immunocompromise
  • Children with cystic fibrosis who have severe disease
  • American Indian and Alaska Native children

If supply is still limited in your particular area, then prioritization should be used as before. Still a bit vague but very important are all the nuances for ordering, administering, and being reimbursed for the product.

Along that same line, RSV may have peaked nationally.

Even with some good news about RSV slowing down, there's still plenty to go around. Also, influenza continues to drive a lot of healthcare usage for all ages around the country. Here is the percentage of emergency department visits due to the various respiratory infections:

Be aware that this site allows you to look just at your local jurisdiction - here is Maryland:

Covid

This week covid deserves a separate heading with a few new twists. Wastewater tracking once again has accurately predicted a surge in infections.

The JN.1 variant has increased rapidly and is projected to be the predominant covid strain in the US, but without any indication (yet) that it has increased virulence.

This might be a good time to review a bit about variants and also some recent covid findings. Variant nomenclature is confusing to me, I can only imagine how the general public sees this. Here is an evolutionary tree from the same CDC weblink as above.

The nomenclature is from the Pango system, but most people are more familiar with the WHO classification: the delta variant (remember those horrible days?) is B.1.617.2 near the left of the diagram. Omicron is represented in both BA.1 and BA.2. Now here's the important part when we consider new variants, immune-escape, and vaccines: JN.1 has developed on the BA.2 side, just like XBB but on a different branch of the tree. Remember that our current vaccines are based on XBB. As I've mentioned previously, XBB vaccine antibody seems to neutralize JN.1 pretty well in the test tube, but all vaccine (and natural infection) immunity declines significantly within a few months after vaccination or immunization. I would still expect the current vaccine to be pretty good for protecting against severe disease with JN.1 infection.

Although near and dear to my heart, I don't usually talk about old folks in this blog. However, a study of old folks in the Netherlands lends support to the idea that current vaccines are effective against new variants. Without going into details, you can see this study has very recent data and show excellent effectiveness for hospitalization and ICU admission for old folks. It's likely this benefit translates to the younger population that of course has lower rates of hospitalization overall.

Another recent study sheds some light on a question I've been wondering about for some time, namely how common asymptomatic covid infection might be in the omicron era. You might recall that one of the early surprises in 2020 was that asymptomatic infection was both common and very important for viral spread. That made the pandemic much more difficult to control. Now we have data from Hong Kong where rather unique epidemiologic circumstances prevailed. With a population of 7.5 million, Hong Kong officials had still had managed to prevent covid spread very effectively prior to the omicron era, with only about 0.5% of the population having been infected. That ended in early 2022, but it also offered researchers an opportunity to look at rates of asymptomatic infection during the omicron period because virtually none of the population had been infected previously. Using antibody testing, they estimated that 16% of the population was infected during the first 6 months of 2022 and that the percentage of asymptomatic cases was at least 42% (taken from those with reported SARS-CoV-2 infections) and possibly as high as 72% (looking at combined reported and unreported infections). Wow. That doesn't necessarily mean we would have those same rates of asymptomatic infection in the US where we've had a very different epidemiologic curve over the years, but I think it's likely we have a lot of asymptomatic covid surrounding us now.

Some good news about long covid, AKA PCC (post-COVID-19 condition) in children. This Canadian study looked at pediatric emergency department data and found that PCC was present in only 0.67% at the12-month follow-up periods in children testing positive for SARS-CoV-2. That's not the only good news part of this; the rate in a control group of children testing negative for covid was 0.16%, suggesting once again that other infections can trigger some of these long term symptoms. We have NIH-funded studies in the US ongoing now, with good control groups, that should go a long way in giving us guidance for managing PCC as well as other long-term conditions triggered by infections.

The Tipping Point

FDA officials, including Peter Marks who is the director of CBER, recently published a viewpoint article about a vaccination tipping point, i.e. the fact that vaccine hesitancy issues have resulted in a severe decrease in immunization coverage, opening us up to major outbreaks soon. I mention this both because it perfectly supports my views expressed in recent weeks but also it gives me a chance to give credit where credit is due. The term "tipping point," as applied here, often has been credited to Malcolm Gladwell. However, his popularization of the term in a sociologic context earlier this century should go to Morton Grodzins who first adapted this for use in explaining racial integration of neighborhoods in the middle of the 20th century. I'm hoping Gladwell credited him.

In Case You Missed These

Two other articles caught my eye this past week. First is a quality improvement article about shortening treatment duration for children with community acquired pneumonia and skin and soft tissue infections. If you're one of those practitioners who still treats these for 10 days (because we have 10 fingers), check it out.

Secondly, I was attracted to a report about variation in rates of how primary pediatric providers use pediatric subspecialty consultations. Although not the main focus of the report, I was most drawn to the mention that the top 2 conditions for using a pediatric infectious diseases specialist were positive tuberculin skin test and inactive tuberculosis. This jives with my personal experience and certainly points to opportunities to lessen use of subspecialty health care. Multiple resources exist for managing latent tuberculosis infection, including the AAP's Red Book, the CDC, and UCSF's Pediatric TB Resource Page.

For the Birds

My first video stars at the bird feeder were a white-breasted nuthatch, maybe a tufted titmouse (looks a lot like the nuthatch, I couldn't figure it out), and a house finch. When I received the bird feeder, I immediately wondered how best to avoid attracting squirrels and other rodents. I did a bit of web searching and then journeyed to my local bird authorities at the Woodend Nature Sanctuary who of course turned out to be the most helpful. I armed my feeder with capsaicin-treated safflower seeds, not a favorite of squirrels and the like, plus birds can't taste the hot pepper. So far the birds seem to like it.

As for me, it appears I've fallen down another rabbit hole, similar to my butterfly fascination. My wanderings have now included a look at how climate change is affecting our bird populations, as projected by the Audubon Society (apologies for using his name, now controversial, but the Society hasn't yet changed it) in their field guide.

Here is how things will change for the white-breasted nuthatch's winter range with a 1.5 C increase in temperature.

For the tufted titmouse

and the house finch

With more severe temperature increases, the ranges are altered more dramatically. I still hope for some action that will reverse these trends.

Published on Leave a comment on Happy Holidays

'Tis the season, both for holidays as well as for infectious diseases. Last week's publications featured a wide variety of articles of interest; I'll try to keep it short. As much as I focus on infectious diseases, now is prime time to spend with friends and family.

Multiplex Stool Testing in Gastroenteritis

Children with acute gastroenteritis presenting to one of five different children's hospitals' on site urgent care or emergency departments submitted stool specimens for multiplex PCR testing. The study plan was interesting. For the first approximately 100 subjects, stools were tested regardless of whether the test was ordered by their clinicians (after informed consent from parents, of course). Then there was an intervention period where clinicians received education about the test performance characteristics and clinical management of the infections that the PCR could detect. Regardless of whether or not you look at the article, you may find these educational materials of use in your practice. I did note that the study was funded by NIH but also by the company that manufactures the PCR tests, plus most of the authors were employees of or received outside funding from the manufacturer. This is important because of high risk of implicit bias affecting the report.

"Clinically relevant" pathogen detection rate rose from 2% in the pre-intervention period to 15% after intervention, and return visits decreased after the intervention. There was a trend towards appropriate treatment given post intervention, though not statistically significant.

Indiscriminate use of multiplex PCR assays in acute gastroenteritis has a great potential to cause unnecessary treatment, especially for C. difficile in young children where the carrier rate is so high. It's not surprising that targeted education would be helpful. Also, because the test cannot determine antibiotic resistance patterns, laboratories would be advised to provide reflex susceptibility testing for selected pathogens that might require antibiotic treatment and also have significant resistance rates.

Covid Morsels

A few tinsel-tinged tidbits about covid caught my eye this week. First of all, CDC had a couple reports both suggesting that rebound after Paxlovid treatment was not clinically significant and no different than after placebo treatment. The more substantial report was a closer look at viral RNA shedding from 2 randomized placebo-controlled trials, from both early and later in the pandemic, involving adults only. Rebound rates were about the same in the treatment and placebo groups, both around 6-8%.

We've seen a wide variety of reports about rebound after Paxlovid, but clearly the weight of evidence suggests that viral rebound after treatment does not result in severe disease and that rebound rates likely are not clinically significant from rebound rates in untreated patients. Rebound concerns should not be a factor in decision to treat with Paxlovid.

Also this past week, the WHO stated that antigen composition for covid vaccines should remain the same for now, i.e. based on the XBB lineage of omicron that continues to represent the vast majority of circulating strains worldwide. The BA.2.86 descendents, including JN.1, are rising but with no big concerns yet about greater virulence or significant lack of protection from the XBB.1.5 monovalent vaccines now in use. As I've stated in previous posts, I've not been commenting on emergence of new subvariants unless/until they are shown to have clinical relevance; so far JN.1 does not meet that threshold.

A multidisciplinary panel of infectious diseases, microbiology, and epidemiology experts published an exhaustive guideline for use of molecular diagnostic testing for covid 19. I struggled with how to summarize all the information, suffice to say that the methodology for guideline development and the evidence behind the recommendations are stated clearly. I'll just present the bottom line summary, but please dig into the article for details if you are interested. Note that, if you haven't already, it would be helpful to identify sites near you where nucleic acid amplification testing (NAAT) with quick turnaround of results is available.

A multinational group of investigators summarized reports of laboratory-acquired infections (LAIs) and accidental pathogen escape from laboratory settings (APELS) between 2000 and 2021. Sixteen APELS were reported and involved anthrax, SARS-CoV (the original), and polio (3 each); Brucella spp and foot and mouth disease virus (2 each); and single episodes of variola virus, Burkholderia pseudomallei, and influenza H5N1 virus escape. LAIs were much more common with a total of 94 reports involving over 300 infected individuals. LAIs more commonly involved Salmonella spp, Brucella spp, and vaccinia virus. Although the study doesn't answer the question of SARS-CoV-2 origin, it certainly can inform measures to prevent lab accidents in the future.

Winter Respiratory Illness Season

Cumulatively our winter respiratory illnesses are increasing. I'm interested to see what the holiday school breaks and travel will do to the epidemic curves. I've been trying very hard to streamline finding current data that also is broken down by location so I can see my own local trends; unfortunately I don't find a single best one-stop shopping site for this purpose.

For general virus surveillance besides covid and influenza, look at the CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). You can then click on links to 4 groups of respiratory viruses (including RSV) as well as to 2 enteric viruses, rotavirus and norovirus. Here's an example of the South Region's (which includes my area of DC, MD, and VA) most recent RSV detection activity:

The CDC's COVID Data Tracker provides an extensive view of various indicators of disease activity, though not of wastewater which is still available at the National Wastewater Surveillance System (see below). Here's a quick view of the Data Tracker's most recent headline:

Wastewater covid continues to rise nationally.

Last but not least, our old friend influenza continues to spread across the country:

Have Your Cake and Eat It Too

I did say at the start this was a time to balance my obsession with all things infectious and my desire to have fun times with family and friends during the holidays, and I'll mention one way to (almost) do both. The annual Christmas issue of the BMJ was released. It always contains a few tongue-in-cheek articles - real research but performed for silly premises. The only infectious diseases-related article this time around was a study of bacterial contamination of hospital coffee machines. Surprisingly to me, the level of true pathogens they found was pretty low. I'm helping with some baking today, fans of the Great British Bake Off will enjoy this article.

However you spend the holidays, please take time to enjoy friends and family.

Published on Leave a comment on It’s Winter Respiratory Season, Complete with Hype

Yes, the winter respiratory illness season has ramped up in the US. Predictably, so has the hype. I even saw a term, "white lung syndrome," tossed out. It's a completely inappropriate description especially when one considers the main lower respiratory disease agent circulating now is a mild one, Mycoplasma pneumoniae.

Before we dive into winter respiratory pathogens, let's touch on a few other noteworthy events from the past week.

Watch Out for Cantaloupes (and many other foods)

CDC announced a new Salmonella outbreak alert this past week, covering 34 states and resulting in over 60 hospitalizations so far. Be particularly cautious of pre-cut cantaloupe products. Perhaps more revealing, however, is the fact that we have 2 other Salmonella outbreaks being monitored now (dry dog food and fresh diced onions) plus 4 others that have ended recently (backyard poultry, raw cookie dough, ground beef, and small turtles). Salmonellosis can mostly be avoided by knowing about high risk situations (e.g. poultry, ground meats, reptiles, poorly washed raw foods) and practicing good handwashing, food washing, and cooking thoroughly, as well as by refrigerating leftovers promptly.

WHO World Malaria Report

WHO released its annual report, and it's no surprise we are behind schedule for decreasing malaria cases worldwide. It's a very long, detailed report even allowing for the fact that some details appear in a few different languages. Some key details:

  • Rapid detection assays have been very helpful in diagnosing Plasmodium falciparum infections in particular, but new mutations in the histidine-rich protein 2 gene may allow these organisms to escape detection.
  • As always, resistance to antimalarials is spreading, requiring ongoing monitoring.
  • Not to be outdone by the pathogen, the vectors (mosquitoes) are increasingly becoming resistant to insecticides. This has led to new recommendations for mosquito netting in malaria-endemic countries.
  • And last, but not least, climate change. Here's a direct quote: "WHO has declared climate change to be the single greatest threat facing humanity."

I liked this graphic for visualizing malaria case distribution geographically.

More Concern for Invasive Group A Streptococcus

The Pan American Health Organism just issued a new alert for iGAS infections in Argentina. This joins a growing list of reports in a number of countries, primarily in Europe. Research is pointing to new M1 mutations with toxin production that might confer increased virulence.

Winter Respiratory Illness Season

Clearly I need to switch from calling this a winter respiratory viral season to a winter respiratory illness season; not all the pathogens are viruses, and of particular note is M. pneumoniae, a free-living organism in the class called Mollicutes. Technically they are bacteria, but they lack a cell wall and I think it's a bit misleading to the general public to refer to them as bacteria. Nonetheless, they aren't viruses. The organism is very difficult to grow in culture, requiring special media and expertise as well as 1-3 weeks incubation, but now it is included in most multiplex respiratory pathogen panels so easier to diagnose. Serologic diagnosis is fraught with false positives, about the least useful serologic testing for human disease that I know of.

"Fried egg" image of M. pneumoniae in culture:

One important thing to know about mycoplasma disease is that it is endemic everywhere, but epidemics occur about every 3 to 7 years and last anywhere from 1 to 2.5 years. I've witnessed this myself several times in my practice in the DC area, and it appears that a new mycoplasma epidemic partially explains the larger numbers of respiratory diseases in Denmark (you may need Google translate) and the Netherlands.

Perhaps more importantly, it's been very difficult to show that antimicrobial treatment has any benefit for illness caused by M. pneumoniae, which is clearly a self-limited infection. Probably if treatment has a benefit it would need to be initiated very early in the disease course. Testing for the organism requires a relatively expensive multiplex PCR assay and probably isn't worthwhile to test for the usually mild "walking pneumonia" version of the infection.

By far the biggest hype in the lay press (and from some congressmen) is the surge in respiratory illness in China, especially in northern regions. However, we do have some reassurance from the WHO taken from review of Chinese reports (Google translate again helps somewhat here). It appears that what is going on is simply an increase in known respiratory pathogens, rather than a new pathogen that China is hiding from us. I can add anecdotally that, as I track reports in real time and compare to the December 2019/January 2020 tracking I was doing, this looks nothing like the new appearance we saw with SARS-CoV-2. That doesn't mean there isn't something new circulating at low levels, but certainly no cause for alarm or to call for travel restrictions.

Remember that China only emerged from their "zero covid" lockdown a year ago, so this is their first full winter respiratory season with most children having no experience with any of these respiratory pathogens the past 4 years. As we saw in the US last winter, this likely produces a temporary situation resulting in increased numbers of cases and increased disease severity.

On the sort of good news side of covid, CDC reported benefits of covid vaccination for children 6 months to 4 years of age from a very recent time period covering July 2022 through September 2023. Vaccine effectiveness (receipt of at least 2 vaccine doses) for preventing acute care visit or hospitalization was 40%, though with a large confidence interval due to the relatively small numbers of events. The somewhat downer side of the report was that only 10% of the 7400+ children in the study had actually received > 2 vaccine doses.

Moving on from covid, RSV activity in RSV-NET is taking off, it is now full-blown RSV season.

Flu is heating up in more parts of the country, but not widespread yet.

Covid also is increasing, and now CDC has a better display for wastewater tracking:

The above is current for the week ending November 25 and predicts we will see a winter increase in covid illness. This is supported by a slight increase in positivity rate in covid testing in CDC data. However, you can see most of the recent uptick in positivity rate is being driven by influenza and RSV. If wastewater is truly predictive, we'll see the covid curve start to rise more dramatically in the coming weeks.

A Chuckle to Share

I loved this brief blurb in the November 20 issue of The New Yorker (I'm way behind in my magazine reading, blame Thanksgiving holidays). Every parent (and grandparent) will identify with this fictional list of communications from a nursery school to parents, announcing outbreaks of lice, pink eye, smallpox, "pirate's gastroenteritis," and rinderpest.

I Didn't Forget Diego Rivera

Last week I challenged you to name the organisms depicted in various Diego Rivera murals as collected in a recent article. According to the authors, figure A represents Salmonella typhi, though that seems a stretch to me. Figure B is easier, it looks a lot like the Gram negative intracellular diplococci seen with gonorrhea. Figure C shows spirochetes, mostly likely syphilis, but D is vague again, some sort of Gram positive intracellular cocci. Take your pick.

Published on Leave a comment on Happy St. Martin’s Day

I was thumbing through my Farmer's Almanac this morning and noticed a mention of "Indian summer" for November 12. That's not a great term to use nowadays, so I'm opting for the European version called St. Martin's summer or day. I never bothered to see what these terms really meant, but I've learned it represents a period officially from November 11 to November 20 where we experience unseasonably warm weather. We've certainly had that recently, though November 11 and 12 in Maryland is back to cool fall weather.

Miscellaneous Vaccine News

I have no idea what a "miscellaneous" vaccine is, I was just desperate for something to title this section.

A new vaccine to prevent chikungunya virus infection was approved by the FDA this week for individuals 18 years and older at increased risk for infection with this mosquito-borne pathogen. It is a live virus vaccine. As with most arboviral illnesses these days, the vector range is expanding as our climate warms, and transmission has occurred within the US. Still, most infections in US residents are acquired via travel to more endemic areas such as Africa, southeast Asia, and Central and South America. The clinical illness is similar to dengue fever and mostly is a miserable but self-limited illness. However, elderly are at risk for complications, principally chronic joint disease. Newborns also are at risk for more severe disease, including death, and it is unknown whether the vaccine virus could be transmitted to the fetus. The package insert includes precautions for use in pregnant people. The main study supporting approval appeared a few months ago and looked primarily at side effects and antibody response, not actual vaccine efficacy. One big caveat, the manufacturer is required to conduct post-marketing studies to ensure that vaccine recipients do not develop a worse form of chikungunya after becoming infected; this is a possibility though not highly likely. For now, I'd consider this mostly as an option for older individuals at very high risk for infection. Most other US residents should wait for further information about the vaccine, but it's good we have this option available.

This past week also saw publication of new data from Singapore about benefits to newborns of covid vaccination of mothers during pregnancy. It was a cohort study, which is a study design slightly more prone to inaccuracies than are randomized controlled trials, but it did show about 40% efficacy in preventing infection in newborns when their mothers were vaccinated during pregnancy. Of interest, pre-pregnancy vaccination of mothers was not effective in preventing newborn infection. The study covered the period from January, 2022, through March 2023. This is yet another reason to encourage covid vaccination for pregnant people, along with pertussis and RSV vaccination. The benefits do extend to their children.

Unfortunately, we also have some disappointing vaccine news in the category of missed opportunities. First, 2 studies from the CDC demonstrated poor influenza vaccine uptake by healthcare providers. In the first report, flu vaccination rates for HCP in acute care hospitals fell from 88.6 - 90.7% in the years 2017-2020 down to 85.9% in 2020-2021 and 81.1% in 2021-2022. We all know that the pandemic made it difficult to access regular health care for many people, but these are workers in acute care hospitals who didn't have that excuse. The second study looked at a broader range of HCP during the 2022-2023 flu season and showed 81.0% flu vaccination rates in acute care hospital employees and a shocking (to me) 47.1% rate for nursing home employees. Up to date covid vaccination status rates were even more depressing: 17.2% and 22.8% in acute care hospitals and nursing homes, respectively. I can understand why some people may choose not to receive these vaccines, but HCP do have a responsibility to protect those for whom they provide care. (IMHO; I'll get off my soap box now.)

Also in the Debbie Downer category, CDC reported that vaccine exemptions for kindergarteners increased for the 2022-2023 school year. The rogues' gallery includes 10 states (Alaska, Arizona, Hawaii, Idaho, Michigan, Nevada, North Dakota, Oregon, Utah, and Wisconsin) having exemption rates above 5%. Idaho easily came out on "top" with a 12.1% exemption rate. The reasons for high exemption rates are complex, note that the list of states doesn't necessarily follow political lines. States that make it more difficult for parents to apply for non-medical, aka philosophical, exemptions have lower exemption rates overall. An oldie but goodie study also stressed that exemption rates vary within a state, and small hot spots with high exemption rates can fuel outbreaks of vaccine-preventable diseases.

Missed Opportunities to Prevent Congenital Syphilis

The CDC was very busy this past week! Another report looked at missed opportunities for prevention of congenital syphilis in 2022. Looking at the 3761 cases of congenital syphilis reported that year, almost 90% of birth parents received inadequate management. This included no or nontimely testing (36.8% of parents) and no or nondocumented (11.2%) or inadequate (39.7%) treatment. I'm hoping our public health infrastructure can be shored up to lower cases of congenital syphilis, now at a 30-year high.

Tripledemic Update

Rather than showing yet another RSV-NET graph, where data are somewhat delayed anyway, I thought I'd mention a bit more about that system. It is set up in 14 states covering about 8% of the US population. Here's what the distribution and data collection looks like:

I'm not sure why (Veteran's Day?) but FLUVIEW did not update this past week, so nothing new to report there. Wastewater covid levels reported by Biobot remain lowish.

No Hasty Pudding Again This Year

I'm starting to help plan a Thanksgiving menu for later this month, and I was reminded of another ill-named item, Indian pudding. It is similar to the British hasty pudding that uses wheat flour rather than cornmeal. I have a wonderful recipe, dated 1958, from the Durgin-Park Restaurant in Boston. Durgin-Park opened in 1742 and closed in 2019, and this dessert was an icon on their menu. The reasons I won't be having it again this year are multiple but include the fact that I'm the only one in my family who likes it and that it contains about 5000 calories per tablespoon (only slight exaggeration). I think I'll just change the name to Durgin-Park pudding for future reference.

Unless otherwise indicated, the content and opinions expressed on this web site are those of the author(s). They are not endorsed by and do not necessarily reflect the views of the George Washington University.
Viewing Message: 1 of 1.
 Notice

This site uses cookies to offer you a better browsing experience. Visit GW’s Website Privacy Notice to learn more about how GW uses cookies.